Trinity Biotech announced that it entered into a $25 million Standby Equity Purchase Agreement (SEPA).
The agreement with an affiliate of financing partner Yorkville Advisors Global provides the Dublin, Ireland-based company with additional funding to augment its commercialization initiatives and support its R&D programs.
Related: nyra health receives €20M to expand AI neuropathy platform
Under the SEPA, Trinity has the right, but not the obligation, to sell up to $25 million in newly issued American Depositary Shares (ADSs) to Yorkville over a period of up to 36 months. The discretionary nature of the facility enables the company to access capital amid market conditions it deems appropriate.
Trinity said the funds can help as it progresses its product pipelines, including the CGM+ offering, a continuous glucose monitor (CGM) under development. The company unveiled the CGM+ next-gen wearable biosensor in July 2025.
With CGM+, the company aims to take on the growing AI wearables market. The company said it has the system in the later stages of device development. The new AI-native CGM combines multi-sensor data with real-time analytics to meet the evolving demands of AI-powered healthcare and wellness.
Trinity reported positive clinical trial results for the system in August 2025. It said the data confirmed that the system offers enhanced user convenience, comfort and reliability. The company believes the clinical validation marks a critical step toward commercializing the platform.
“Our key strategic initiatives at Trinity Biotech are to grow our existing business profitably and to advance our exciting innovation agenda, including our flagship development, CGM+,” said Trinity Biotech President and CEO John Gillard. “This financing agreement provides us with significant additional capability to progress these initiatives.”
